fda warning letters glp-1 november 2025 october compounding Pharmacovigilance Assessment of Compounded GLP-1 Receptor Agonists: Insights From the FDA Adverse FDA unleashes warning letters to – fda warning glp-1 november 2025

IntroductionIn the realm of weight loss, a promising player has emerged - GLP-1, short for glucagon-like peptide-1

It is fueling your body in order to be able to do that

By day four, something felt different

Itching or Tenderness Itching and mild pain are also common injection site reactions with GLP-1s like tirzepatide, semaglutide, or liraglutide

New guidelines in Canada are the first to recognize obesity as a chronic illness, which if followed by the US and others could grow the market value significantly

The Role of Oral Anti-Diabetic Drugs Oral anti-diabetic drugs remain the most widely used treatment, particularly in cases where lifestyle modifications alone are insufficient